专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060105030A1 Transdermal therapeutic system 审中-公开
公开(公告)号：US20060105030A1
公开(公告)日：2006-05-18
申请号：US11087754
申请日：2005-03-24
申请人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7053 , A61K31/48
摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

2. 发明申请

US20070243240A9 Transdermal therapeutic system 审中-公开
公开(公告)号：US20070243240A9
公开(公告)日：2007-10-18
申请号：US11087754
申请日：2005-03-24
申请人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7053 , A61K31/48
摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

3. 发明申请

US20050220855A1 Transdermal therapeutic system 审中-公开
公开(公告)号：US20050220855A1
公开(公告)日：2005-10-06
申请号：US11116279
申请日：2005-04-28
申请人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： C07D457/00 , A61K9/70 , A61K31/437 , A61K31/48 , A61K47/02 , A61K47/04 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/28 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61L15/58 , A61P5/08 , A61P5/24 , A61P13/02 , A61P13/10 , A61P15/00 , A61P15/08 , A61P15/14 , A61P25/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P43/00
CPC分类号： A61K9/7061 , A61K31/48
摘要： Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered. The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer.

4. 发明申请

US20070134309A1 Agent containing ergoline for transdermal application 审中-公开
标题翻译：含麦角林的药物用于经皮应用
公开(公告)号：US20070134309A1
公开(公告)日：2007-06-14
申请号：US10570262
申请日：2004-05-30
申请人： Reinhard Horowski , Johannes Tack , Katalin Bostedt , Dirk Schenk
发明人： Reinhard Horowski , Johannes Tack , Katalin Bostedt , Dirk Schenk
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K31/48 , A61K47/10
摘要： The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic polymer.
摘要翻译：本发明涉及一种含有麦角蛋白化合物，优选碘化镧的透皮治疗系统，其中麦角蛋白化合物稳定化。氧化敏感的麦角蛋白化合物通过至少一种脂溶性自由基清除抗氧化剂，优选二叔丁基甲基苯酚，二叔丁基甲氧基苯酚，生育酚或泛醌和碱性聚合物的组合来稳定。

5. 发明授权

US08668925B2 Transdermal delivery of hormones without the need of penetration enhancers 有权
标题翻译：激素的透皮递送，而不需要渗透促进剂
公开(公告)号：US08668925B2
公开(公告)日：2014-03-11
申请号：US11008642
申请日：2004-12-10
申请人： Thomas Langguth , Stefan Bracht , Michael Dittgen , Petra Huber , Dirk Schenk
发明人： Thomas Langguth , Stefan Bracht , Michael Dittgen , Petra Huber , Dirk Schenk
IPC分类号： A61F13/00 , A61K9/70 , A61F13/02 , A61L15/16
CPC分类号： A61K47/32 , A61K9/70 , A61K9/7053 , A61K9/7061 , A61K9/7076 , A61K31/56 , A61K31/567 , A61K31/57
摘要： The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.
摘要翻译：本发明涉及包含含有低含量激素的药物含量层（如孕二烯酮）和任选的雌激素（如乙炔雌二醇）的贴剂。在将补片施用于妇女时，在稳定状态条件下达到至少1.0ng / ml Gestodene的血浆水平，而不需要在含药层中掺入渗透促进剂或渗透促进剂。令人满意的激素水平也可以在至少1周的时间内达到，使补丁适用于女性避孕方法，每周施用补片的概念。

6. 发明申请

US20170071869A1 TRANSMUCOSAL DELIVERY OF LAQUINIMOD BY ORAL PATCHES 审中-公开
标题翻译：通过口头贴子传递LAQUINIMOD
公开(公告)号：US20170071869A1
公开(公告)日：2017-03-16
申请号：US15123208
申请日：2015-03-13
申请人： Ralph Stefan , Hans Juergen Mika , Claudia Lauer , Dirk Schenk , Sabine Prohl
发明人： Ralph Stefan , Hans Juergen Mika , Claudia Lauer , Dirk Schenk , Sabine Prohl
IPC分类号： A61K9/70 , A61K31/4704 , A61K9/00
CPC分类号： A61K9/70 , A61K9/006 , A61K31/4704
摘要： The subject invention provides an oral patch comprising: a) a liner; and b) a film composition thereon, the film composition comprising (i) laquinimod in an amount of about 0.1%-20% by weight of the film composition, and (ii) one or more film forming agents in a total amount of about 40%-90% by weight of the film composition. The subject invention also provides a method for delivering laquinimod across the oral mucosa of a subject, or for treating a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to the human subject an oral patch as described herein. The subject invention also provides an oral patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.
摘要翻译：本发明提供口腔贴剂，其包含：a）衬垫; 和b）其上的薄膜组合物，所述薄膜组合物包含（i）按所述薄膜组合物重量计约0.1％-20％重量的拉喹莫德，和（ii）一种或多种总成型量的成膜剂％-90重量％的膜组合物。本发明还提供了一种用于递送穿过受试者的口腔粘膜的laquinimod或用于治疗患有多发性硬化症形式的人类受试者的方法，其包括向所述人类受试者施用本文所述的口腔贴剂。本发明还提供如本文所述的用于治疗患有多发性硬化症形式的人类受试者的口腔贴剂。

7. 发明授权

US06521191B1 Permeation cell for in vitro determination of skin permeation of pharmaceutical drugs 失效
标题翻译：用于体外测定药物皮肤渗透的渗透细胞
公开(公告)号：US06521191B1
公开(公告)日：2003-02-18
申请号：US09611199
申请日：2000-07-06
申请人： Dirk Schenk , German Gassner
发明人： Dirk Schenk , German Gassner
IPC分类号： B01L300
CPC分类号： G01N13/00 , G01N2013/003 , G01N2013/006
摘要： A permeation cell for the in vitro determination of the permeation of pharmaceutical active ingredients through the skin, having a donor chamber (34) and an acceptor chamber (4) that is separable therefrom, a window lying between them for receiving sealingly a skin membrane and sealingly closable filling and emptying openings at both chambers, characterized in that the acceptor chamber (4) is in the form of a cylindrical vessel that is upright during operation, having a closure (8; 50; 80) at its upper end and a side window opening (6) in the region near its base, and the donor chamber (34) is in the form of a connection piece that joins onto the acceptor chamber radially and can be closed at its outer end, with the exception of its closure (8; 50; 80) the acceptor chamber (4) is inserted removably into a housing (10) that fits closely around it, which housing has, in the region of the window opening (6) of the acceptor chamber, a corresponding slightly wider opening (30), and the connection piece forming the donor chamber (34) is screwed removably onto the housing concentrically with the window opening (6). As a result, the permeation cell gains stability, it is as easy to manipulate as it is to manufacture, auxiliary means for attaching the skin membrane not being required, and the acceptor chamber has only a small dead volume. By constructing the housing (10) essentially in block form, several such permeation cells can be used next to one another in a common heating and/or stirring device.
摘要翻译：用于体外测定药物活性成分通过皮肤的渗透细胞的渗透细胞，其具有供分离室（34）和与其分离的受体室（4），位于它们之间的窗口用于密封地接受皮肤膜和在两个腔室处可密封地关闭的填充和排空开口，其特征在于，所述受体室（4）是在操作期间是直立的圆柱形容器的形式，在其上端具有封闭件（8; 50; 80）在其底部附近的区域中的窗口（6），并且供体室（34）是连接件的形式，其径向连接到受体室上，并且可以在其外端封闭（除了其封闭件 8; 50; 80）受体室（4）可拆卸地插入到紧密配合的壳体（10）中，该壳体在受体室的窗口（6）的区域中具有对应的较宽的打开（30）和连接形成供体室（34）的吸入件与窗口（6）同心地可拆卸地拧到壳体上。结果，渗透细胞获得稳定性，与制造一样容易操作，用于附着不需要的皮肤膜的辅助装置，并且受体室仅具有小的死体积。通过构造基本上为块状的壳体（10），可以在共同的加热和/或搅拌装置中使用相邻的几个这样的渗透池。

8. 发明授权

US08486443B2 UV stable transdermal therapeutic plaster with a UV absorbing adhesive layer separated from the drug matrix 有权
标题翻译：紫外线稳定的经皮治疗膏药与药物基质分开的紫外吸收胶粘剂层
公开(公告)号：US08486443B2
公开(公告)日：2013-07-16
申请号：US10545826
申请日：2004-02-04
申请人： Jochen Schuhmacher , Manfred Suesse , Michael Dittgen , Stephan Mletzko , Jan-Peter Ingwersen , Thomas Langguth , Dirk Schenk , Hubert Kaffl
发明人： Jochen Schuhmacher , Manfred Suesse , Michael Dittgen , Stephan Mletzko , Jan-Peter Ingwersen , Thomas Langguth , Dirk Schenk , Hubert Kaffl
IPC分类号： A61K9/70
CPC分类号： A61K31/567 , A61K9/0014 , A61K9/7084 , A61K47/08 , A61K47/12 , A61K47/22 , A61M35/00
摘要： The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.
摘要翻译：本发明涉及由背层，至少一种含有活性物质的基质和任选的取出膜和UV-辐射吸收剂组成的UV稳定透皮治疗系统（TTS）。含有所述紫外线吸收剂的粘合剂层被布置在背层和含有活性物质的基质之间，所述活性物质尽可能远离表面，分离层设置在包含所述紫外线吸收剂的粘合剂层和含有活性物质的基质，该活性物质尽可能远离活性物质和紫外线吸收剂不可渗透的表面。本发明的透皮治疗系统表现出高稳定性，并且没有含有光敏物质的现有TTS的不便。

9. 发明申请

US20060251707A1 Uv stable transdermal therapeutic plaster 有权
标题翻译： Uv稳定透皮治疗膏药
公开(公告)号：US20060251707A1
公开(公告)日：2006-11-09
申请号：US10545826
申请日：2004-02-04
申请人： Jochen Schumacher , Manfred Suesse , Michael Dittgen , Stephan Mletzko , Jan-Peter Ingwersen , Thomas Langguth , Dirk Schenk , Hubert Kaffl
发明人： Jochen Schumacher , Manfred Suesse , Michael Dittgen , Stephan Mletzko , Jan-Peter Ingwersen , Thomas Langguth , Dirk Schenk , Hubert Kaffl
IPC分类号： A61K9/70
CPC分类号： A61K31/567 , A61K9/0014 , A61K9/7084 , A61K47/08 , A61K47/12 , A61K47/22 , A61M35/00
摘要： The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.
摘要翻译：本发明涉及由背层，至少一种含有活性物质的基质和任选的取出膜和UV-辐射吸收剂组成的UV稳定透皮治疗系统（TTS）。含有所述紫外线吸收剂的粘合剂层被布置在背层和含有活性物质的基质之间，所述活性物质尽可能远离表面，分离层设置在包含所述紫外线吸收剂的粘合剂层和含有活性物质的基质，该活性物质尽可能远离活性物质和紫外线吸收剂不可渗透的表面。本发明的透皮治疗系统表现出高稳定性，并且没有含有光敏物质的现有TTS的不便。

10. 发明申请

US20050142175A1 Transdermal delivery of hormones without the need of penetration enhancers 有权
标题翻译：激素的透皮递送，而不需要渗透促进剂
公开(公告)号：US20050142175A1
公开(公告)日：2005-06-30
申请号：US11008642
申请日：2004-12-10
申请人： Thomas Langguth , Stefan Bracht , Michael Dittgen , Petra Huber , Dirk Schenk
发明人： Thomas Langguth , Stefan Bracht , Michael Dittgen , Petra Huber , Dirk Schenk
IPC分类号： A61K31/56 , A61K9/70
CPC分类号： A61K47/32 , A61K9/70 , A61K9/7053 , A61K9/7061 , A61K9/7076 , A61K31/56 , A61K31/567 , A61K31/57
摘要： The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.
摘要翻译：本发明涉及包含含有低含量激素的药物含量层（如孕二烯酮）和任选的雌激素（如乙炔雌二醇）的贴剂。在向女性施用贴剂时，在稳定状态条件下达到至少1.0ng / ml的Gestodene的血浆水平，而不需要在含药层中掺入渗透促进剂或渗透促进剂。令人满意的激素水平也可以在至少1周的时间内达到，使补丁适用于女性避孕方法，每周施用补片的概念。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式